vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $168.4M, roughly 1.6× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 91.8%). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 10.6%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ALAB vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $168.4M |
| Net Profit | $45.0M | — |
| Gross Margin | 75.6% | — |
| Operating Margin | 24.7% | 50.6% |
| Net Margin | 16.6% | — |
| Revenue YoY | 91.8% | 143.7% |
| Net Profit YoY | 82.0% | — |
| EPS (diluted) | $0.25 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $168.4M | ||
| Q3 25 | $230.6M | $87.3M | ||
| Q2 25 | $191.9M | $82.4M | ||
| Q1 25 | $159.4M | $65.0M | ||
| Q4 24 | $141.1M | $69.1M | ||
| Q3 24 | $113.1M | $51.6M | ||
| Q2 24 | $76.8M | $73.8M | ||
| Q1 24 | $65.3M | $137.7M |
| Q4 25 | $45.0M | — | ||
| Q3 25 | $91.1M | $-31.3M | ||
| Q2 25 | $51.2M | $-12.7M | ||
| Q1 25 | $31.8M | $-40.5M | ||
| Q4 24 | $24.7M | — | ||
| Q3 24 | $-7.6M | $-29.5M | ||
| Q2 24 | $-7.5M | $-61.9M | ||
| Q1 24 | $-93.0M | $61.0M |
| Q4 25 | 75.6% | — | ||
| Q3 25 | 76.2% | — | ||
| Q2 25 | 75.8% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.0% | — | ||
| Q3 24 | 77.7% | — | ||
| Q2 24 | 77.9% | — | ||
| Q1 24 | 77.4% | — |
| Q4 25 | 24.7% | 50.6% | ||
| Q3 25 | 24.0% | -11.4% | ||
| Q2 25 | 20.7% | 8.6% | ||
| Q1 25 | 7.1% | -34.0% | ||
| Q4 24 | 0.1% | -6.4% | ||
| Q3 24 | -7.9% | -31.0% | ||
| Q2 24 | -31.7% | 3.5% | ||
| Q1 24 | -127.1% | 52.5% |
| Q4 25 | 16.6% | — | ||
| Q3 25 | 39.5% | -35.9% | ||
| Q2 25 | 26.7% | -15.4% | ||
| Q1 25 | 20.0% | -62.2% | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | -6.7% | -57.2% | ||
| Q2 24 | -9.8% | -83.9% | ||
| Q1 24 | -142.5% | 44.3% |
| Q4 25 | $0.25 | $0.32 | ||
| Q3 25 | $0.50 | $-0.16 | ||
| Q2 25 | $0.29 | $-0.06 | ||
| Q1 25 | $0.18 | $-0.21 | ||
| Q4 24 | $1.23 | $-0.14 | ||
| Q3 24 | $-0.05 | $-0.15 | ||
| Q2 24 | $-0.05 | $-0.33 | ||
| Q1 24 | $-1.77 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $-302.0M |
| Total Assets | $1.5B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $167.9M | ||
| Q3 25 | $140.4M | $92.4M | ||
| Q2 25 | $162.3M | $86.1M | ||
| Q1 25 | $86.4M | $114.6M | ||
| Q4 24 | $79.6M | $144.8M | ||
| Q3 24 | $126.1M | $144.7M | ||
| Q2 24 | $421.1M | $189.3M | ||
| Q1 24 | $696.1M | $226.6M |
| Q4 25 | $1.4B | $-302.0M | ||
| Q3 25 | $1.3B | $-451.4M | ||
| Q2 25 | $1.1B | $-433.5M | ||
| Q1 25 | $1.0B | $-426.2M | ||
| Q4 24 | $964.8M | $-388.7M | ||
| Q3 24 | $889.6M | $-370.2M | ||
| Q2 24 | $845.3M | $-344.2M | ||
| Q1 24 | $808.8M | $-294.3M |
| Q4 25 | $1.5B | $465.9M | ||
| Q3 25 | $1.4B | $364.0M | ||
| Q2 25 | $1.3B | $347.1M | ||
| Q1 25 | $1.1B | $324.0M | ||
| Q4 24 | $1.1B | $343.8M | ||
| Q3 24 | $983.1M | $314.1M | ||
| Q2 24 | $915.5M | $352.3M | ||
| Q1 24 | $864.9M | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | $45.2M |
| Free Cash FlowOCF − Capex | $76.6M | — |
| FCF MarginFCF / Revenue | 28.3% | — |
| Capex IntensityCapex / Revenue | 6.9% | 0.0% |
| Cash ConversionOCF / Net Profit | 2.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $45.2M | ||
| Q3 25 | $78.2M | $-4.3M | ||
| Q2 25 | $135.4M | $-31.4M | ||
| Q1 25 | $10.5M | $-22.6M | ||
| Q4 24 | $39.7M | $-35.0M | ||
| Q3 24 | $63.5M | $-35.3M | ||
| Q2 24 | $29.8M | $-7.2M | ||
| Q1 24 | $3.7M | $53.8M |
| Q4 25 | $76.6M | — | ||
| Q3 25 | $65.9M | — | ||
| Q2 25 | $133.3M | — | ||
| Q1 25 | $6.0M | — | ||
| Q4 24 | $24.3M | — | ||
| Q3 24 | $46.8M | $-35.5M | ||
| Q2 24 | $28.5M | $-7.3M | ||
| Q1 24 | $228.0K | $53.8M |
| Q4 25 | 28.3% | — | ||
| Q3 25 | 28.6% | — | ||
| Q2 25 | 69.5% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 17.2% | — | ||
| Q3 24 | 41.4% | -68.7% | ||
| Q2 24 | 37.1% | -9.9% | ||
| Q1 24 | 0.3% | 39.0% |
| Q4 25 | 6.9% | 0.0% | ||
| Q3 25 | 5.3% | 0.0% | ||
| Q2 25 | 1.1% | 0.0% | ||
| Q1 25 | 2.8% | 0.0% | ||
| Q4 24 | 10.9% | 0.0% | ||
| Q3 24 | 14.8% | 0.3% | ||
| Q2 24 | 1.7% | 0.1% | ||
| Q1 24 | 5.2% | 0.1% |
| Q4 25 | 2.12× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 2.64× | — | ||
| Q1 25 | 0.33× | — | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALAB
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
